PTO/SB/06a (05-07)
Approved for use through 09/30/2007 CMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTIMENT OF COMMERCE to a collection of information unless it contains a valid OMS control number. Application Number 10595412

	, delinearion realization		100001112	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Filing Date		2006-08-15	
	First Named Inventor Yamaguchi		guchi	
	Art Unit		1617	
	Examiner Name	to be assigned		
	Attamen Desket Number VDO NEC D4		KDO NEC D4	

	U.S.PATENTS					Remove					
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	Date	Name of Patentee or Applicant Reli		Releva	ges,Columns,Lines where elevant Passages or Relevant gures Appear		
	1	6592894		2003-07	-15	Zarif, et al.		whole o	ocument		
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	of cited Decument		s,Columns,Lines where vant Passages or Relevant es Appear			
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	Add		
				FOREIG	SN PA1	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Applicant of cited		vhere Rel	or Relevant	т
	1	2003-172493	JP		A	2003-06-20	Toppan Printing Co	Lid.	rhole docu	ment	×
	2	1995/009862	wo			1995-04-13	Ciba-Geigy AG		rhole docu	ment	
	3	93/15720	wo		A1	1993-08-19	Vestar, Inc.	,	rhole docu	ment	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

A

(Not for submission under 37 CFR 1.99)

Examiner Name bo be assigned Attorney Docket Number KPD-NEG-P1

If you wish to add additional Foreign Patent Document citation information please click the Add button

pplication Number		10595412
iling Date		2006-08-15
irst Named Inventor Yama		guchi
rt Unit		1617
xaminer Name	to be	assigned
ttorney Docket Number		KPO-NEG-P1

Remove

Examiner Initials*	Cite No	clude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item odd an appropriate (a serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), bitisher, city and/or country where published.
	1	MAGUCHI, YOKO et al., Application of Hard Retinoic Acid Nanoparticles for Skin Regeneration, Drug Delivery stem, May 2003, 221, Vol. 18, No. 3.
	2	MMAGUCHI, Y et al., Controlled Delivery of all-trans Retinoic Acid-CacO3 Nanoparticles, 29th Annual Meeting of the ntrolled Release Society in Collaboration with the Korean Society for Biomaterials, Final Program July 20-25 (2002), stract.
	3	MMGUCHI, YOKO et al., investigation of the Properties of Sustained Release in All-trans Retinoic Acid (ATRA)- CO3 Nanoparticles, The Journal of Pharmaceutical Science and Technology, March 2002, 12, Vol. 62, pplement.
	4	C. S. et al., Receptor-mediated Delivery of All Trans-retance Acid to Hepaticryte Using Poly(L-lactic acid) intoparticles Coated with Galactose-carrying Polystyrene, Journal of Controlled Release, November 2001, 7-15, Vol
	5	ORDANO, GIOVANNI G. et al., Sustained Delivery of Retinoic Acid from Microspheres of Biodegradable Polymer in IR, Investgative Ophthelmology and Visual Science, August 1983, 2743-2751, Vol. 34, No. 9.
	6	remational Search Report, Form PCT/ISA/210, for International Application PCT/JP03/13180.
If you wis	h to a	additional non-patent literature document citation information please click the Add button Add
		EXAMINER SIGNATURE
Examiner	Signa	e Date Considered
***********		W MICH CO. D. C. W. L. C.

NON-PATENT LITERATURE DOCUMENTS

See find. Codes of USPTO Planto Documents at year, USPTO, DOV on MEPP 901.04. * Enter office that issued the document, by the hey-leter code (WIPO Standard ST.3.). **Poly-leapness petrated commands, he in-decision on the year of the region of the Engerer manta procession the settle in under the patient document. *
**Indi of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **Applicant is to place a check mark here if Employable processions as standard.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10595412
Filing Date		2006-08-15
First Named Inventor Yama		guchi
Art Unit		1617
Examiner Name	to be assigned	
Attorney Docket Number		KPO-NEG-P1

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 :	and 1.98 to make th	e appropriate selection(s):
---------------	------------	---------------------	-----------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(42).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Manette Dennis/	Date (YYYY-MM-DD)	2007-07-08
Name/Print	Manette Dennis	Registration Number	30 623

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bs 1449, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bs 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the principal principal patients and the principal principal patients and the principal principal patients and the principal patients and the principal patients and the principal patients are patients. The principal patients are provided to the principal patients and the principal patients are patients. The principal patients are principally and the principal patients are principally as a patient of the patients and the principal patients are principally as a patient of the patients and the patients are provided to the patients and the patients are principally as a patient patients are principally as a patient patients and the patients are principally as a principal patient patients. The patients are patients are patients and the patients are patients and the patients are patients and the patients are patients. The patients are patients are patients are patients and the patients are patients and the patients are patients are patients. The patients are patients are patients are patients and the patients are patients are patients are patients. The patients are patients. The patients are patients are patients ar

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.